GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » 3-Year ROIIC %

Zydus Lifesciences (BOM:532321) 3-Year ROIIC % : 27.13% (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Zydus Lifesciences's 3-Year ROIIC % for the quarter that ended in Mar. 2024 was 27.13%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Zydus Lifesciences's 3-Year ROIIC % or its related term are showing as below:

BOM:532321's 3-Year ROIIC % is ranked better than
76.8% of 1030 companies
in the Drug Manufacturers industry
Industry Median: 0.79 vs BOM:532321: 27.13

Zydus Lifesciences 3-Year ROIIC % Historical Data

The historical data trend for Zydus Lifesciences's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zydus Lifesciences 3-Year ROIIC % Chart

Zydus Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
3-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.55 11.77 13.56 47.99 27.13

Zydus Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
3-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.99 - - - 27.13

Competitive Comparison of Zydus Lifesciences's 3-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zydus Lifesciences's 3-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's 3-Year ROIIC % falls into.



Zydus Lifesciences 3-Year ROIIC % Calculation

Zydus Lifesciences's 3-Year ROIIC % for the quarter that ended in Mar. 2024 is calculated as:

3-Year ROIIC %=3-Year Incremental Net Operating Profit After Taxes (NOPAT)**/3-Year Incremental Invested Capital**
=( 36163.8064 (Mar. 2024) - 25164.9182 (Mar. 2021) )/( 247672 (Mar. 2024) - 207132 (Mar. 2021) )
=10998.8882/40540
=27.13%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Zydus Lifesciences  (BOM:532321) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Zydus Lifesciences 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zydus Lifesciences (BOM:532321) Business Description

Traded in Other Exchanges
Address
Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines